[1] 中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016, 43(10): 405. doi: 10.3969/j.issn.1000-8179.2016.10.001
[2] 余小情, 丛阳, 唐蕾, 等. 术前超声漏诊甲状腺癌颈部淋巴结转移的原因分析[J]. 中国超声医学杂志, 2017, 33(2): 10.
[3] 彭梅, 张学珍, 王圣应, 等. 甲状腺结节的超声声像图多元回归分析[J]. 蚌埠医学院学报, 2008, 33(3): 356. doi: 10.3969/j.issn.1000-2200.2008.03.045
[4] 张晨嵩, 喻大军, 李靖, 等. 纳米碳示踪技术在甲状腺癌手术中对甲状旁腺的保护作用[J]. 蚌埠医学院学报, 2016, 41(3): 311.
[5] WANG X, TAN J, ZHENG W, et al. A retrospective study of the clinical features in papillary thyroid microcarcinoma depending on age[J]. Nucl Med Commun, 2018, 39(8): 713. doi: 10.1097/MNM.0000000000000859
[6] LUO Y, ZHAO Y, CHEN K, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma[J]. J Endocrinol Invest, 2019, 42(2): 227. doi: 10.1007/s40618-018-0908-y
[7] 张克铭. 甲状腺微小癌的病理特征和淋巴结转移分析[D]. 蚌埠: 蚌埠医学院, 2018.
[8] FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856. doi: 10.1093/annonc/mdz400
[9] ZHANG LY, LIU ZW, LIU YW, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients[J]. World J Surg, 2015, 16(8): 3361.
[10] 徐余兴, 帅剑锋, 汪会, 等. 单侧cN0甲状腺乳头状癌颈中央区淋巴结转移的危险因素分析[J]. 安徽医学, 2020, 41(12): 1375. doi: 10.3969/j.issn.1000-0399.2020.12.001
[11] KIM E, CHOI JY, KOO DO H, et al. Differences in the characteristics of papillary thyroid microcarcinoma ≤ 5 mm and >5 mm in diameter[J]. Head Neck, 2015, 37: 694. doi: 10.1002/hed.23654
[12] 黄春, 邓畅, 苏新良. cN0甲状腺微小乳头状癌淋巴结转移危险因素分析[J]. 中国普外基础与临床杂志, 2021, 4(7): 1.
[13] WELCH HG, DOHERTY GM. Saving thyroids-overtreatment of small papillary cancers[J]. N Engl J Med, 2018, 379(4): 310. doi: 10.1056/NEJMp1804426
[14] ZHAO C, JIANG W, GAO Y, et al. Risk factors for lymph node metastases (LNM) in patients with papillary thyroid microcarcinoma(PTMC): role of preoperative ultrasound[J]. J Int Med Res, 2017, 45(3): 1221. doi: 10.1177/0300060517708943
[15] WANG Y, GUAN Q, XIANG J. Nomogram for predicting central lymphnode metastasis in papillary thyroid microcarcinoma: a retrospective cohort study of 8668 patients[J]. Int J Surg, 2018, 55: 98. doi: 10.1016/j.ijsu.2018.05.023
[16] SHENG L, SHI J, HAN B, et al. Predicting factors for central or lateral lymph node metastasis in conventional papillary thyroid microcarcinoma[J]. Am J Surg, 2020, 220(2): 334. doi: 10.1016/j.amjsurg.2019.11.032
[17] 程鸣鸣, 柴芳, 柴东奇, 等. 甲状腺微小乳头状癌发生颈中央区淋巴结转移的风险[J]. 中国老年学杂志, 2020, 40(12): 2512. doi: 10.3969/j.issn.1005-9202.2020.12.015
[18] ZHENG X, PENG C, GAO M, et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1, 587 patients[J]. Cancer Biol Med, 2019, 16(1): 121. doi: 10.20892/j.issn.2095-3941.2018.0125
[19] XU Y, XU L, WANG J. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution[J]. J Surg Res, 2018, 221: 128. doi: 10.1016/j.jss.2017.08.007
[20] 焦小平. BRAF~(V600E)基因突变与甲状腺乳头状癌关系的临床研究[D]. 蚌埠: 蚌埠医学院, 2012.
[21] LI F, CHEN G, SHENG C, et al. BRAF V600E mutation in papillary thyroid microcarcinoma: a meta-analysis[J]. Endocr Relat Cancer, 2015, 22(2): 159. doi: 10.1530/ERC-14-0531
[22] JI W, XIE H, WEI B, et al. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma[J]. Int J Clin Exp Pathol, 2019, 12(9): 3492.
[23] LIANG J, LI Z, FANG F, et al. Is prophylactic central neck dissection necessary for cN0 differentiated thyroid cancer patients at initial treatment? A meta-analysis of the literature[J]. Acta Otorhinolaryngologica Italica, 2017, 37(1): 1. doi: 10.14639/0392-100X-1195